The president said he would build on the Medicare drug-price negotiation program begun under Joe Biden, but supports a change sought by the pharmaceutical industry.

President Donald Trump wants Congress to change a policy that gives certain drugs longer protection from drug price negotiations in Medicare, a fix that could address one of the drug industry’s top complaints with the Biden-era law.

The order calls for lowering the price of insulin for low-income patients or people who are uninsured, as well as lowering the price of injectable epinephrine.